Cancer patient acceptance, understanding, and willingness to pay for pharmacogenetic testing (PGT)

Autor:	Sohaib Masroor, Ekta Hasani, Bradley De Souza, Wei Xu, Chung-Kwun Amy Wong, Kimberly Tobros, Geoffrey Liu, Xin Qiu, Abul Kalam Azad, Amalia M Issa, Natasha B. Leighl, Henrique Hon, Sinead Cuffe, Natalie Rozanec, Shabbir M.H. Alibhai, Graham McFarlane
Rok vydání:	2012
Předmět:	Cancer Research medicine.medical_specialty business.industry Cancer therapy Alternative medicine Cancer medicine.disease Patient acceptance Surgery Oncology Willingness to pay medicine business Intensive care medicine Pharmacogenetics
Zdroj:	Journal of Clinical Oncology. 30:6005-6005
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2012.30.15_suppl.6005
Popis:	6005 Background: PGT offers the potential to improve cancer therapy through the use of specialized tests that can predict the level of efficacy and/or toxicity of specific treatments in an individual. However, there is currently little knowledge concerning cancer patient attitudes towards such testing in the clinical setting. Methods: We interviewed a broad cross-section of 278 cancer patients (20% lung, 19% breast, 20% colorectal, 40% other) using hypothetical time, efficacy, toxicity and willingness-to-pay trade-off PGT scenarios. Results: 153 potentially curable patients and 125 incurable patients received a separate series of trade-off scenarios. For curative patients, 70% accepted chemo that had a 5% absolute improvement in cure rate and
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::abe94d80a516b373cc08bfb6b7b8b7df https://doi.org/10.1200/jco.2012.30.15_suppl.6005 Zobrazit plný text záznamu